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Original article
Background: in HiV infection, dynamic marginal structural models 
have estimated the optimal cD4 for treatment initiation to minimize 
aiDS/death. the impact of cD4 observation frequency and grace 
periods (permitted delay to initiation) on the optimal regimen has 
not been investigated nor has the performance of dynamic marginal 
structural models in moderately sized data sets—two issues that are 
relevant to many applications.
Methods: to determine optimal regimens, we simulated 31,000,000 
HiV-infected persons randomized at cD4 500–550 cells/mm3 to regi-
mens “initiate treatment within a grace period following observed 
cD4 first <x cells/mm3,” x = 200, 210, …, 500. natural history and 
treatment response were simulated using previous model estimates 
from caScaDe data. Optimal treatment regimens for the observa-
tion frequencies and grace periods were defined by highest 10-year 
aiDS-free survival. to evaluate the performance of dynamic mar-
ginal structural models, we simulated 1000 observational studies 
(n = 3,000) with cD4-dependent treatment initiation.
Results: Decreasing the frequency of cD4 measurements from 
monthly to every 3, 6, and 12 months increased the optimal regi-
men from a cD4 level of 350 (10-year aiDS-free survival, 0.8657) 
to 410 (0.8650), 460 (0.8634), and 490 (0.8564), respectively. Under 
a regimen defined by x = 350 with annual cD4s, 10-year aiDS-free 
survival dropped to 0.8304. extending the grace period from 1 to 
3 or 6 months, with 3-monthly cD4s, maintained the optimal regi-
men at 410 for 3 months and increased it to 460 for 6 months. in 
observational studies with 3-monthly cD4s, the mean (Se) estimated 
optimal regimen was 402 (76), 424 (66), and 430 (63) with 1-, 3-, and 
6-month grace periods; 24%, 15%, and 14% of estimated optimal 
regimens resulted in >0.5% lower aiDS-free survival compared with 
the true optimal regimen.
Conclusions: the optimal regimen is strongly influenced by cD4 
frequency and less by grace period length. Dynamic marginal struc-
tural models lack precision at moderate sample sizes.
(Epidemiology 2014;25: 194–202)
Treatment of many diseases is determined by a person’s time-varying characteristics; such a treatment regimen 
is termed dynamic. One example is HiV infection, where, 
to minimize time on treatment when side effects and resis-
tance can develop, treatment initiation may be delayed until 
some immunodeficiency is apparent, indicated by low values 
of the biomarker, cD4 count. Dynamic treatment regimens 
can be defined by the observed cD4 threshold below which 
treatment is initiated. a large randomized trial comparing two 
cD4-based initiation regimens is ongoing1; in the meantime, 
researchers have attempted to answer this question across a 
broad range of regimens using observational data.2–5 Dynamic 
treatment questions also arise in other contexts; for example, 
when and how to treat type 2 diabetes are determined by 
fasting blood glucose or Hba1c levels,6 and diagnosis and 
hence treatment of hypertension are based on blood pres-
sure.7 Such questions usually imply the presence of a time-
dependent confounder affected by prior treatment, like cD4 
in HiV infection. in this situation, causal methods such as 
the g-formula,8,9 g-estimation of structural nested models,10  
or dynamic marginal structural models11,12 are required for 
unbiased estimation.
in any application, the optimal treatment regimen may 
depend on several factors, including observation frequency and the 
grace period (permitted delay from the time treatment is indicated, 
such as cD4 below a specified threshold, to initiation), but their 
effects have not been systematically investigated nor has the per-
formance of dynamic marginal structural models been explored in 
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realistically-sized data sets. We addressed these questions by simu-
lating large randomized trials and realistically-sized observational 
studies using HiV infection as an example and assessed whether 
the observational dynamic marginal structural model analysis cor-
rectly identifies the optimal regimen defined by the randomized 
simulation. We outline the theory of dynamic marginal structural 
models, describe our simulation methods, present our results, and 
conclude with a discussion of our findings and recommendations.
METHODS
Definitions and Notation
We defined 31 regimens by “initiate treatment within g 
months of observed cD4 first <x cells/mm3” where x = 200, 210, 
…, 500 and g is the grace period (the time period during which 
treatment initiation is still considered compliant with regimen 
x). Because we consider immediate initiation to be “within the 
first month,” we denote this as g = 1. thus, we consider true 
grace periods to be given by g ≥ 2, in contrast to cain et al,12 
who considered immediate treatment initiation as m(= g – 1) = 
0. a benefit of a grace period is that, if a person’s observed cD4 
count rises slightly from the nadir before treatment initiation, 
then the person may still be considered compliant with some 
regimens with which they otherwise may not have been.
let Tx be the time from study entry to aiDS/death for 
a participant under regimen x. if we could observe Tx for all 
participants and regimens, or if a large number of participants 
were randomized to each regimen x, then the optimal regimen 
x would simply be that which minimizes the aiDS/death risk 
across all participants–reflected, for example, by the probability 
of remaining aiDS-/death-free 10 years after baseline. in prac-
tice, we observe only a subset of regimens for each participant, 
and the regimen(s) that each participant is observed to follow 
may be confounded by their prognosis. Under the assumption 
of consistency,13 T, the time to aiDS/death under each observed 
regimen, x, is Tx. For those regimens x with which a participant is 
not compliant throughout follow-up, Tx is counterfactual.
We divide time into monthly intervals, t = 1, 2, …, and 
define Cx(t) as an indicator for artificial censoring, which equals 
0 if the participant’s observed data are still compliant with regi-
men x before time t and equals 1 otherwise (eappendix, http://
links.lww.com/eDe/a753). let A(t) be an indicator for whether 
treatment was initiated before t, Y(t) an indicator for whether 
aiDS/death was experienced before t, and Qx(t) an indicator 
for whether observed cD4 was <x cells/mm3 before t. then12:
C t j t
A j
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A j g Q j Y tx( ) ( ) ,+ − = − = =( )1 1 1 1 0       when
(and compliance is not applicable if Y(t) = 1 since then that per-
son is no longer at risk for the event). that is, participants are 
censored if they initiated treatment before becoming eligible 
under a given regimen (observed cD4 ≥ x cells/mm3). no par-
ticipants are censored during the grace period but are censored 
at the last (gth) month of the grace period if they have not ini-
tiated treatment by that time. those who are not censored at 
that point (ie, initiated treatment within the grace period) will 
remain uncensored for the rest of their follow-up (eappendix, 
http://links.lww.com/eDe/a753).
Dynamic Marginal Structural Model Methods
a dynamic marginal structural cox model may be 
defined for the time to aiDS/death by:
λ λ α βTx t x V t g x t V( | , ) ( )exp{ ( , ) }= +0
where λ0 ( )t  is the baseline hazard, V represents baseline 
covariates, and α and β are to be estimated. g(x, t) is some 
function of the regimens x including an interaction with time 
t, which is essential. For example, for a given participant, 
the regimens x = 200 and 350 are the same until cD4 is first 
observed <350 cells/mm3; therefore, the hazard ratio between 
the two regimens cannot be constant over time.
all participants are considered to be compliant with all 
regimens initially; they are artificially censored from regimens 
when they first become noncompliant with that regimen (as 
above). in practice, estimation requires data expansion, duplicat-
ing each participant’s data for the 31 regimens, while they remain 
compliant with each. the artificial censoring process is likely to 
be informative; we take account of this using inverse probability 
weighting. Under the assumption of no unmeasured confounders 
for censoring and outcome, and given baseline and time-updated 
covariates and treatment history, the weight for a participant on 
regimen x at time t is the inverse probability of remaining uncen-
sored to t. conditional on baseline and time-updated covariates 
and treatment history, this is the same as the probability of the 
observed treatment history to time t.11,12,14 With a grace period, 
regimens require further specification; we defined them as: “initi-
ate treatment within g months of cD4 first <x cells/mm3, such that 
there is a uniform probability of starting in each of the months 1, 
2, …, g.”12 informally, participants who initiate treatment at any 
point during the grace period are upweighted to account for those 
censored at the end of the grace period because they did not initi-
ate by that time. the (nonstabilized) weights are estimated as:
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where I ⋅[] is the indicator function, overbars indicate his-
tory, qx is the time cD4 is first observed <x cells/mm
3, and 
p j A j A j Y j L jA( ) Pr ( ) | ( ) , ( ) , ( )= = − = = −{ }0 1 0 0 1  is the 
probability of not initiating treatment at time j, given covari-
ate history and no initiation by time j – 1. the first component 
of this equation is the probability of remaining uncensored 
while cD4 ≥ x cells/mm3, that is, off treatment. the second 
component spans the grace period l = 1, ..., g, that is, covering 
the g months after treatment is indicated by the regimen and 
cD4 history. the denominator is based on the probabilities 
of observed treatment, that is, the probability of remaining 
off treatment while treatment-naive during the grace period, 
multiplied by the probability of initiating treatment when (if) 
treatment is initiated during the grace period. the numerator 
serves to upweight those participants who initiated during 
the grace period to account for those who are censored at the 
end of the grace period due to noninitiation of treatment and 
maintains the uniform distribution of treatment initiation over 
the grace period. We can estimate pA(j) from the data using a 
pooled logistic regression model. the treatment probabilities 
are independent of regimen x, so we fit this model on a data 
set with one observation per participant (per month). When 
we expand, as above, at any time, the weights are constant for 
each participant across all regimens with which they are still 
compliant. While stabilized weights may be used to increase 
precision, this is not guaranteed,12 and their calculation is non-
trivial when assuming uniform initiation across a grace period. 
We therefore used nonstabilized weights, truncated at 20.
We used weighted discrete-time survival regression 
(pooled logistic regression) to approximate the cox model15:
 
Pr ( ) | ( ) , ( ) , ,
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where g(x) and f(t) are smooth functions of the regimens x and 
time t, respectively. the parameters α β γ δ, , ,{ } are estimated 
using weighted maximum pseudolikelihood, with robust stan-
dard errors. in real applications, administrative (end-of-study) 
censoring can be considered independent, but early loss to fol-
low-up can be incorporated using independent inverse prob-
ability weighting.
Simulation Study
We simulated cD4 trajectories monthly over 10 years 
for HiV-infected participants with observed baseline cD4s 
distributed uniformly in 500–550 cells/mm3 (reflecting rela-
tively early presentation to care). We used a piecewise-linear 
mixed-effects model for square root underlying cD4, with 
change point at treatment initiation and 1 year later. true 
cD4 was determined as the underlying cD4 plus Brownian 
motion (superior to standard mixed-effects model, based on 
data from caScaDe [concerted action on Seroconversion 
to aiDS and Death in europe]).16 Observed cD4 was the true 
cD4 plus measurement error. correlations between cD4 at 
treatment initiation and subsequent (initial and after 1 year) 
slopes were negative, and slopes could be negative, particu-
larly after 1 year and with high cD4 counts before initiating 
antiretroviral therapy (eappendix, http://links.lww.com/eDe/
a753). that is, we incorporated a potential penalty for early 
treatment initiation, meaning that cD4 levels could decline 
after treatment initiation (as observed in caScaDe data).
let u ti
Y ( ) represent the probability of aiDS/death at a 
given time t; this was simulated dependent on true cD4 and 
treatment as follows:
u t
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where cD4T(t – 1) is the true cD4 at time t – 1, and the param-
eters were chosen such that the probability of aiDS/death was 
0.01 and 0.0005 off treatment at cD4s of 200 and 500 cells/
mm3, respectively, and correspondingly 0.006 and 0.0002 on 
treatment (based on previous work by the caScaDe col-
laboration and by Babiker et al16; eappendix, http://links.lww.
com/eDe/a753).
Determining the Optimal Regimen via 
Simulated Randomized Trials
to determine optimal regimens for treatment initiation 
in these populations, we simulated large randomized trials, 
each with 31,000,000 persons randomly allocated to follow 
one of the 31 regimens. For each trial, the cD4 observation 
frequency was fixed at 1, 3, 6, or 12 months, and the grace 
period was also fixed at one of these values. For a given 
grace period >1 month, to achieve uniform treatment initia-
tion across the grace period, participants identified for initia-
tion (based on their randomized regimen and observed cD4) 
were randomly allocated to initiate in one of the grace period 
intervals, each with probability 1/g. We initially defined the 
optimal regimen to be that maximizing the 10-year aiDS-free 
survival estimated by Kaplan–Meier procedures; no under-
lying model was assumed to avoid implausible proportional 
hazards assumptions. We also applied a least-squares smooth-
ing procedure (bandwidth 0.2) as the 10-year aiDS-free sur-
vival estimates did not always vary smoothly, despite the large 
sample size.
Evaluating the Performance of Dynamic 
Marginal Structural Models via Simulated 
Observational Studies
to evaluate the performance of dynamic marginal 
structural models in realistically-sized data sets, under sce-
narios with a cD4 observation frequency of 3 months and 
grace periods of 1, 3, and 6 months, we simulated 1000 obser-
vational studies of 3000 persons, with the same populations 
as the randomized trials but with treatment initiation prob-
ability dependent on cD4. aiDS-free survival was estimated 
by weighted Kaplan–Meier analysis, with each member of 
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the risk set for each regimen and at each time point weighted 
as per equation 1 and pooled logistic regression (equation 
2; the inverse probability-weighted pooled logistic regression 
models approximating a cox dynamic marginal structural 
model), with the optimal regimen determined as that yield-
ing the highest 10-year aiDS-free survival. note that the 
grace periods were a step in the data analysis, not in the data 
generation.
the following model was used to determine treatment 
initiation (probability given by 1 – pA(t)), based on caScaDe 
data (eappendix, http://links.lww.com/eDe/a753):
log
( )
( )
. . ( )
1
4 62 0 412 4
−
= −
p t
p t
tA
A
CD O
where cD4O(t) is the observed cD4 at time t.
While grace periods may occur in practice, due to 
time required to receive and act on cD4 results, a clinician 
may wish to know whether to initiate treatment immediately 
(1-month grace period). there may also be efficiency gains 
in permitting a grace period in observational analyses due 
to fewer censored treatment initiations, albeit at potentially 
increased risk of bias in answering the question of interest 
(impact of immediate treatment initiation). We evaluated this 
bias-variance trade-off, treating the optimum regimen identi-
fied from the simulated randomized trials as the true optimum 
value with a 1-month grace period, and estimated the bias, 
mean square error (variance + bias2), and relative efficiency 
of various grace period lengths (relative efficiency = variance/
variance under reference method, chosen as pooled logistic 
regression because this is typically used in practice,5,12 with a 
1-month grace period).17
RESULTS
Simulated Randomized Trials
For the simulated trial with monthly cD4s and a 1-month 
grace period, the cD4 trajectories for an example participant 
randomized to the regimen x = 200 are shown in Figure 1 
and illustrate the large measurement error in this biomarker. 
Baseline characteristics for the n = 1,000,000 simulated par-
ticipants randomized to each of the regimens x = 200, 350, 
and 500 were comparable across regimens (table 1; similar 
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FIGURE 1. CD4  trajectory  (underlying  slope,  true,  and 
observed CD4) for an example participant in a simulated trial 
randomized to the regimen “initiate treatment within 1 month 
of observed CD4 first <200 cells/mm3.” True CD4 incorporates 
Brownian motion, and observed CD4 also incorporates mea-
surement error (see text for more details).
TABLE 1. Baseline Characteristics and Treatment for n = 1,000,000 Simulated Participants Randomized to Each of the 
Regimens x = 200, 350, 500 (CD4s Observed Monthly, 1-month Grace Period)
Regimens Given by x
200 350 500
Baseline
  Observed cD4 count (cells/mm3) 525 (513 to 538) 525 (512 to 537) 525 (512 to 538)
  true cD4 count (cells/mm3) 525 (457 to 598) 525 (457 to 598) 525 (457 to 598)
  annual slope, square root scale –1.10 (–1.44 to –0.76) –1.10 (–1.44 to –0.76) –1.10 (–1.44 to –0.76)
treatment
  no. persons observed to initiate treatment; no. (%) 783,766 (78) 952,144 (95) 995,522 (>99)
  time to initiation (months)a 37 (21 to 62) 10 (4 to 25) 3 (2 to 5)
  Observed cD4 count at initiation (cells/mm3)a 175 (154 to 189) 313 (282 to 333) 432 (379 to 469)
  true cD4 count at initiation (cells/mm3)a 275 (240 to 313) 425 (381 to 472) 503 (441 to 565)
  initial annual slope after initiation, square root scalea,b 3.42 (2.16 to 4.68) 2.78 (1.52 to 4.04) 2.51 (1.24 to 3.77)
  annual slope 1 year after initiation, square root scalea,b 0.41 (0.30 to 0.52) 0.01 (–0.10 to 0.12) –0.17 (–0.31 to –0.03)
  Percentage of follow-up time spent on treatment; % 49 79 94
Unless otherwise stated, values are median (interquartile range).
ain those participants who were observed to initiate treatment.
bas assigned at treatment initiation.
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for other regimens, not shown). treatment patterns were 
as expected between regimens (eg, those randomized to 
x = 500 initiated earliest). the median observed cD4 counts 
at initiation were 175 (interquartile range = 154–189), 313 
(282–333), and 432 (379–469) cells/mm3 for x = 200, 350, 
and 500, respectively, yet the corresponding true values were 
275 (240–313), 425 (381–472), and 503 (441–565) cells/mm3. 
thus, the large measurement error illustrated in Figure 1 has a 
substantial impact, raising the true cD4 at initiation.
the 10-year aiDS-free survival was 0.8278, 0.8657, 
and 0.8587 for regimens x = 200, 350, and 500, respectively, 
indicating that, of these three regimens, x = 350 was optimal 
(Figure 2a). indeed, across all 31 regimens, the optimal was 
x = 350 (table 2 and Figure 2B).
Decreasing the cD4 observation frequency to every 3, 
6, and 12 months increased the optimal regimen to 410, 460, 
and 490, respectively (1-month grace period); yet, despite 
increasing the optimal regimen’s cD4 threshold, the 10-year 
aiDS-free survival dropped only modestly, from 0.8657 to 
0.8650, 0.8634, and 0.8564, respectively. Under a 350 regi-
men (optimal when cD4s were observed monthly) with 3-, 6-, 
and 12-month cD4s, the 10-year aiDS-free survival dropped 
slightly more (from 0.8657 to 0.8616, 0.8528, and 0.8304, 
respectively). Under a 410-regimen (optimal when cD4s 
were observed every 3 months), the 10-year aiDS-free sur-
vival declined from 0.8650 to 0.8615 and 0.8484 with 6- and 
12-monthly cD4s, respectively.
With monthly cD4s, extending the grace period from 
1 to 3, 6, and 12 months maintained or increased the optimal 
regimen from 360 (10-year aiDS-free survival = 0.8657) to 
360 (0.8644), 370 (0.8631), and 380 (0.8598), respectively. 
With 3-monthly cD4s, the optimal regimens under 3- and 
6-month grace periods were 410 (0.8638) and 460 (0.8625), 
respectively. With 6-monthly cD4s, the optimal regimen 
under a 6-month grace period was 460 (0.8603).
Sensitivity analyses varying the initial off-treatment 
rate of cD4 decline (table 3) showed little variation in the 
optimal regimen when cD4s were observed every 6 or 12 
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FIGURE 2. AIDS-free survival based on the simulated randomized trial with CD4s observed monthly and 1-month grace period. A, 
Over 10 years, for the three regimens x = 200, 350, and 500. B, By regimens x = 200, 210, ..., 500 and illustrating determination 
of the optimal regimen from the 10-year AIDS-free survival by regimen plot.
TABLE 2. Optimal Regimens as Determined from the 
Randomized Trials (Raw 10-year AIDS-free Survival) by CD4 
Observation Frequency and Grace Period
CD4 
Observation 
Frequency 
(Months)
Grace Period (Months)
1 3 6 12
1 350 (0.8657) 360 (0.8644) 370 (0.8631) 380 (0.8598)
3 410 (0.8650) 410 (0.8638) 460 (0.8625) —
6 460 (0.8634) — 460 (0.8603) —
12 490 (0.8564) — — —
note: Simulations initially explored the impact of varying grace period for fixed 
cD4 observation frequency of 1 month and of varying cD4 observation frequency for 
1-month grace period. Subsequent simulations focused on the most realistic scenarios: 
“—” indicates that a specific simulation was not performed.
TABLE 3. Optimal Regimens as Determined from the 
Randomized Trials (Raw 10-year AIDS-free Survival) by CD4 
Observation Frequency and Rate of Initial (Off-treatment) 
CD4 Decline
CD4 Observation 
Frequency 
(Months)
Initial (Off-treatment) CD4 Decline
Slow Regular Fast
1 310 (0.8731) 350 (0.8657) 360 (0.8601)
3 380 (0.8720) 410 (0.8650) 460 (0.8592)
6 460 (0.8705) 460 (0.8634) 460 (0.8569)
12 490 (0.8671) 490 (0.8564) 500 (0.8471)
note: estimated under 1-month grace period. “regular” cD4 decline corresponds 
to 1-month grace period in table 2; “slow” and “fast” decline correspond to the lower 
and upper quartiles, respectively, of the pretreatment cD4 trajectories in caScaSe data 
(eappendix, http://links.lww.com/eDe/a753).
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months. However, particularly when cD4s were observed 
every 3 months, populations with slower cD4 decline had a 
lower optimal regimen, and those with faster cD4 decline had 
a higher optimal regimen.
applying the local smoothing, there were small changes 
in the estimated optimal regimens compared with those deter-
mined directly by Kaplan–Meier analysis: from 350 to 360 
with monthly cD4s/1-month grace period, from 380 to 400 
with monthly cD4s/12-month grace period, from 460 to 420 
with cD4s observed every 3 months/6-month grace period, and 
from 460 to 470 with cD4s observed every 6  months/6-month 
grace period. these changes all occurred in regions where the 
aiDS-free survival was fairly constant.
Simulated Observational Studies
in the observational studies (n = 3000 participants) with 
cD4 levels observed every 3 months, the mean estimated 
optimal regimen was 395 (standard error = 70), 418 (57), and 
420 (60) with 1-, 3-, and 6-month grace periods, respectively, 
under Kaplan–Meier analysis, and 402 (76), 424 (66), and 430 
(63), respectively, under pooled logistic regression (Figure 3). 
the corresponding percentages of estimated optimal regimens 
associated with aiDS-free survival that were more than 0.5% 
worse than under the true optimal regimen (from the trials) 
were 23%, 12%, and 16% under Kaplan–Meier, and 24%, 
15%, and 14% under pooled logistic regression. note that 
approximately 10% of simulations using Kaplan–Meier and 
25% using pooled logistic regression estimated the optimal 
regimen at the maximum considered (x = 500).
assuming the desired inference is under 1-month grace 
period, the bias was –15 (mean square error = 5,099; rela-
tive efficiency = 0.84), 8 (3,273; 0.55), and 10 (3,644; 0.61) 
with 1-, 3-, and 6-month grace periods, respectively, under 
Kaplan–Meier and –8 (5,874; 1.00 [reference]), 14 (4,537; 
0.75), and 20 (4,333; 0.68), respectively, under pooled logis-
tic regression. Bias was similar using local smoothing of the 
Kaplan–Meier estimates (data not shown). Simulation of 
large observational studies (n = 100,000) indicated no bias in 
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FIGURE 3. Optimal regimens as estimated by the simulated observational studies (n = 3000 participants in each of 1000 studies 
for each scenario) with CD4s observed every 3 months, with the optimal regimen estimated either by raw Kaplan–Meier analysis 
or pooled logistic regression, and with grace periods of 1, 3, or 6 months. Numbers in bold grey above the solid vertical lines are 
the optimal regimen as determined from the corresponding randomized trials (after smoothing), and numbers in grey above the 
dashed vertical lines indicate the highest regimen with >0.5% lower AIDS-free survival versus the true optimal regimen. Numbers 
in black are the mean (standard error) [percentage less than the dashed grey line] across the 1000 simulated observational studies.
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the results as estimated by weighted Kaplan–Meier (results 
not shown).
DISCUSSION
We have demonstrated via a simulation based on HiV 
infection that frequency of observation has a major impact on 
the optimal regimen for treatment initiation. lengthening the 
grace period (permitted delay for treatment initiation) has less 
influence, at least for 3–6 months. in HiV infection, these find-
ings have implications for the generalizability of results from 
studies in high-income to low-income countries; in the latter, 
cD4 levels are typically measured less frequently, although 
similar aiDS-free survival may be achieved, provided the 
optimal regimen (cD4 threshold for treatment initiation) is 
raised accordingly. Our results also highlight that it is essen-
tial for future studies using causal analysis methods to report 
their observation frequency (as observed in the data) and the 
grace period (as assumed for analysis) to enable comparisons 
and judgments as to the relevance of findings to different set-
tings. Furthermore, it is likely that observation frequencies 
will vary within and between persons and cohorts; the impact 
of such variation warrants further exploration and suggests 
that reporting measures of the spread of observation frequen-
cies within and between cohorts is important.
it is interesting to consider why cD4 observation fre-
quency has a greater impact on the optimal regimen than does 
grace period length. there is an asymmetry due to regimens 
being defined by cD4 counts dropping below a threshold. For 
example, when cD4 counts were observed monthly, the same 
participants were identified for treatment initiation, regardless 
of whether a grace period of 1 or 12 months was permitted. 
However, if a cD4 count observed on the monthly schedule 
indicated treatment initiation but that cD4 count was not 
observed on the 12-monthly cD4 count schedule, then that 
participant would not have been identified for treatment initia-
tion under the less-frequent cD4 observation until sometime 
later. therefore, to identify such persons for treatment initia-
tion, the optimal regimen would need to be higher. Measure-
ment error also has a larger impact on observation frequency 
than it does on grace period. For example, if each random 
low cD4 count that happened to be observed on a monthly, 
but not yearly, schedule led the person to be started on treat-
ment early, then the optimal regimen would be reduced with 
more frequent observation. requiring a confirmatory cD4 
count for initiation might reduce the impact of measurement 
error (although not random fluctuation). However, in prac-
tice, relatively few people have confirmatory counts before 
starting treatment, making implementation of such optimal 
regimens difficult. the delay to initiation assuming uniform 
treatment initiation across a grace period also has less effect 
than a similar length delay to next cD4 observation. this is 
because even with a 12-month grace period, for example, half 
of the (upweighted) participants are assumed to initiate within 
6 months of reaching the threshold.
With sufficient data and under the necessary assump-
tions, the dynamic marginal structural model methods are 
unbiased,11 as we showed in simulations of very large obser-
vational studies (n = 100,000 participants). However, where 
there are large natural fluctuations and measurement error in 
the biomarker that defines the regimens, and where the event 
rate is low, as in our example, the methods may lack preci-
sion in realistically-sized cohorts. this was exacerbated by the 
broadly constant aiDS-free survival at high cD4s, meaning 
that any single analysis may yield an estimate for cD4 for 
optimal initiation quite far from the true value. this was illus-
trated by the large number of simulations, suggesting that the 
optimal regimen was the maximum considered (cD4 = 500), 
particularly under the pooled logistic regression approach. 
Of note, the methods, particularly pooled logistic regression, 
performed better in further less-realistic simulations with a 
clearer “peak” in the optimal regimen (results not shown). 
Our findings reinforce the current view that large collabora-
tive clinical cohorts are required to answer such causal ques-
tions. they also suggest that Kaplan–Meier estimates may be 
preferred and that interpretation should consider how the pre-
dicted outcome varies by regimen (Figure 2B) and recognize 
that precision may be low. However, if this curve is fairly flat, 
then the implications for clinical practice from not identifying 
the exact optimal regimen may not be severe, despite the lack 
of precision.
the recent extension of these methods to incorporate 
grace periods is an attempt to address the relatively limited 
data typically available, by decreasing censored treatment ini-
tiations and hence increasing power. However, the potential 
implications of these extended methods in realistic scenarios 
have not previously been systematically explored. Our find-
ings suggest that observational studies in similar  resource-rich 
settings, with cD4 observation frequencies of every 3 months, 
should use a 3-month grace period in analysis, as this increases 
precision with little bias. longer grace periods were associ-
ated with increased bias. However, across the grace periods 
considered, the efficiency gains were perhaps smaller than 
might have been anticipated. Our results also suggest that a 
grace period of a length similar to the observation frequency 
would be reasonable in other settings.
grace periods are typically referred to simply by their 
length, but this does not provide a full definition of the regi-
men. Previously, most researchers have upweighted only those 
observed to initiate treatment in the last interval of the grace 
period,3,5,12 considering regimens of the form “initiate treat-
ment in the last month of the grace period if not already on 
treatment.” However, we preferred to upweight all those who 
initiated during the grace period, considering regimens of 
the form “initiate treatment within the grace period such that 
there is a uniform probability of starting treatment in each of 
the months within the grace period” to avoid upweighting a 
potentially small and unrepresentative subset of participants. 
cain et al12 provide further discussion on this.
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this simulation study has several limitations. First, 
alternative regimen definitions could be applied. For exam-
ple, finer or coarser cD4 categorizations could be used, 
although our choice is considered practically and clinically 
a good compromise.12 regimens could include initiation at 
even higher cD4 thresholds, although in practice few peo-
ple maintain such high cD4 levels after seroconversion.18 
regimens could also incorporate different frequencies of 
cD4 measurement between and within individuals, possibly 
dependent on participants’ covariates. Furthermore, regimens 
could be defined based on other time-independent or time-
dependent covariates (such as HiV viral load), although esti-
mation may be hampered by the limited data available for 
each regimen if many factors are incorporated. identification 
of the optimal regimen may alternatively be based partly on 
the population-level benefits.19
large measurement error and random fluctuation are 
inherent challenges in the application of these methods, caus-
ing large proportions of records with observed treatment 
initiation to be artificially censored from all regimens if the 
treatment initiations occurred at cD4 counts above the nadir, 
even when permitting a grace period of up to 6 months to cen-
sor fewer treatment initiations. if cD4 counts declined lin-
early while treatment-naive (ie, in the absence of Brownian 
motion and measurement error), this censoring would no lon-
ger occur. alternative approaches, such as defining a regimen 
to require two cD4 counts below each threshold x for treat-
ment initiation, could perhaps reduce censored treatment ini-
tiations as an alternative or even parallel approach to include 
a grace period. However, if cD4 counts are not consistently 
confirmed in an observational study (as is typically the case), 
then enforcing this in analysis is unlikely to be beneficial and 
may leave only unrepresentative participants uncensored. a 
second approach could be to use cD4 history to better esti-
mate current observed cD4 (eg, using smoothing), to poten-
tially reduce the impact of measurement errors. However, 
given their size, some censoring of treatment initiations seems 
inevitable in our application.
a further limitation is that our simulation models incor-
porated a negative correlation between cD4 at treatment ini-
tiation and long-term slope thereafter, based on previous 
caScaDe data modeling. this correlation may be driven by 
persons who initiated treatment early but subsequently stopped. 
therefore, our simulation may have underestimated the benefit 
of early treatment initiation at high cD4, assuming that treat-
ment is continued once initiated. However, one could argue 
that the observed and modeled cD4 trajectories in the caS-
caDe data are likely to mimic what would happen in practice, 
regardless of underlying reasons. Of note, if a penalty for early 
treatment initiation had not been incorporated via this negative 
correlation, and cD4 never declined while on treatment, then it 
would always be optimal to initiate treatment immediately.
the determination of optimal treatment regimens is 
heavily dependent on time. in this example, sufficient time 
must be allowed for the biomarker to decrease and hence 
for differences in the outcome to emerge between the regi-
mens. We simulated 10-year follow-up, but optimal regimens 
may have been different if longer follow-up was considered. 
For example, Figure 2a shows that the cD4 < 350 regimen 
is optimal only after 7 years, with the cD4 < 500 regimen 
optimal before this. in addition, other metrics, for example, 
a  cD4-based or quality of life–based metric,5,11 or restricted 
mean survival20 may yield different optimal regimens.
Other approaches such as the g-formula or g-estimation 
of structural nested models could be used as alternatives to 
dynamic marginal structural models. g-estimation of struc-
tural nested models has the potential to be more efficient than 
dynamic marginal structural models and has fewer parametric 
assumptions than the g-formula.21 However, structural nested 
models are less robust to model misspecification and are not 
intuitive to apply. Dynamic marginal structural models more 
closely resemble standard methods and so their implementa-
tion and interpretation are more straightforward. However, 
these dynamic models require the assumption of positivity 
(ie, at all combinations of values of covariate and treatment 
histories which occur in the population, there is a nonzero 
probability of following each of the regimens under consider-
ation).13 in addition, the artificial censoring process required 
for the application of dynamic marginal structural models 
may result in reduced power. While the g-formula can easily 
incorporate highly complex dynamic regimens, it is computa-
tionally intensive and perhaps most useful when a small num-
ber of dynamic regimens are to be compared.
there are similarities between the application of the 
g-formula and our observational simulation studies. in our 
analyses, we a priori defined the covariate, treatment, and 
outcome distributions, conditional on covariate and treatment 
history, based on previous work with caScaDe data, while 
the g-formula estimates the parameters of these distributions 
from the data. then, similar to the g-formula, we simulated a 
cohort using those distributions; however, while the g-formula 
would also incorporate the treatment regimen of interest, our 
approach incorporated this after expansion of the simulated 
cohort by censoring individuals when no longer compliant. 
the final step of our simulation studies was to estimate the 
outcome, as in the g-formula, except that inverse probability 
weighting was applied to account for the potentially infor-
mative censoring of noncompliant participants. in addition, 
estimation of the outcome is performed separately for each 
regimen under the g-formula, whereas the dynamic marginal 
structural models allowed us to model the outcome across all 
regimens at once.
in summary, causal analysis methods provide an oppor-
tunity to address many questions from observational studies, 
which could otherwise not be considered without the possi-
bility of major bias due to time-dependent confounding. it is 
infeasible to conduct sufficient randomized controlled trials 
to address all these questions. However, we have shown that 
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answers from causal analyses may depend strongly on their 
implementation, in ways that may not be obvious to a casual 
reader. this is a particular concern when comparing results 
between studies. researchers conducting such analyses 
should be aware of these limitations, describe the full details 
of implementation, and present multiple sensitivity analyses 
to delineate the effect of their assumptions on the results.
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